Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05697861 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status changed: Recruiting → Enrolling by Invitation
    • Site details revised at 4 of 4 sites
    v9
  2. Re-verified, no change to tracked fieldsv8
  3. Study sites: 3 to 4v7
  4. Re-verified, no change to tracked fieldsv6
  5. Site details revised at 1 of 3 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Site details revised at 1 of 3 sitesv4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of May 2023 to Jul 10, 2023
    • Site details revised at 3 of 3 sites
    v3
  3. Start date: Mar 2023 to May 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.
Trial Details
NCT Number NCT05697861
Lead Sponsor Intellia Therapeutics
Conditions
(from sponsor)		 Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
Related terms Amyloid Neuropathies, Familial
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov